20 articles
A landmark meta-analysis of 29,625 people finds plasma p-tau217 detects Alzheimer's pathology with ~88% sensitivity and specificity.
A fully automated plasma p-tau217 test accurately identifies Alzheimer's pathology across 1,767 patients in primary and secondary care settings.
Plasma eMTBR-tau243 outperforms current tau biomarkers in identifying tau tangle pathology and predicting cognitive decline in Alzheimer's disease.
Researchers developed plasma p-tau217 clocks that predict when cognitively healthy people will develop Alzheimer's symptoms within 3-4 years.
New blood test using 7,000 proteins creates biological aging clock and disease trajectory that better predicts Alzheimer's risk than current methods.
A 7-protein plasma panel predicts Alzheimer's with AUC >0.88, validated across 10,000+ samples from multiple cohorts and platforms.
Comprehensive review reveals TPE could shift from reactive treatment to preventative therapy for cardiovascular, metabolic, and neurological aging.
New evidence-based guideline defines performance thresholds for blood tests that can replace costly PET and CSF testing in specialized AD care.
A licensing deal for 9 specialized Tau antibodies may help distinguish Alzheimer's from other brain diseases years before symptoms appear.
French study reveals antibody trajectory patterns that could guide treatment decisions in thrombotic thrombocytopenic purpura.
Scientists discover tau isn't just an Alzheimer's villain — it's essential for encoding lasting memories in healthy neurons.
A ctDNA analysis of the TheraP trial identifies genomic biomarkers that predict response to Lu-177-PSMA-617 in metastatic prostate cancer.
Scientists discover Fyn kinase can seed Alzheimer's-like Tau tangles from scratch via membrane-anchored microclusters, revealing a new therapeutic target.
Breakthrough study reveals distinct molecular fingerprints of tau protein across dementia types, enabling precise diagnosis and targeted treatments.
Scientists used gene editing to discover cellular pathways that control toxic tau protein accumulation in neurons, revealing new therapeutic targets.
Randomized trial finds therapeutic plasma exchange improves lab values but doesn't reduce 30-day mortality in acute liver failure patients.
Multi-center study reveals therapeutic plasma exchange may improve survival in severe amatoxin poisoning cases.
First controlled study shows therapeutic plasma exchange safely reduces biological age markers across multiple molecular pathways.
A landmark 14-year UK Biobank study maps 3,089 protein-CVD associations, revealing causal biomarkers and drug repurposing opportunities.
New Phase 2/3 trial data show buntanetap improved cognition in early-stage Alzheimer's patients positive for pTau217, hinting at disease-modifying effects.
